[Source]
AmerisourceBergen has been selected by Karyopharm Therapeutics to support XPOVIO™ (selinexor). AmerisourceBergen is providing a unified commercialization approach for XPOVIO™, which was approved by the U.S. Food and Drug Administration (FDA) on July 3, 2019. XPOVIO™ is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
In the United States, there are 32,000 new cases of multiple myeloma, a cancer of plasma cells, each year. There are approximately 130,000 patients living with multiple myeloma in the United States today. The blood cancer is characterized by disease-related symptoms, including fatigue or weakness, unusual bleeding or bruising, and bone pain or fractures. Patients who suffer from relapsed and refractory multiple myeloma have an average five to nine month survival rate depending on the number of prior lines of therapy. XPOVIO™ inhibits the function of a nuclear export protein called XPO1 and induces the accumulation of tumor suppressor proteins in the cell nucleus, leading to the selective death of cancer cells.
“We are proud to work with Karyopharm to introduce a new treatment option to our customers for patients affected by this rare disease,” said Joe Cappello, Senior Vice President, Global Specialty & Branded Product Strategy & Access at AmerisourceBergen. “At AmerisourceBergen, we act as one unified business, offering a breadth of services and custom commercialization plans to our manufacturing partners. Through this seamless experience, we can improve product performance and increase patient access to specialized therapies like XPOVIO™.”